ストックスクリーナーアプリを入手
644.48
0.46%
-3.01
アフターアワーズ：
644.48
Argen X Se Adr (ARGX) 最新ニュース
Argenx Vaults 3,659% With Profit Growth Seen In Triple Digits; Earnings Next As Stock Hits Highs - Investor's Business Daily
BBVA Argentina ADR (BBAR) Shares Rise Despite Market Challenges - The News Heater
Telecom Argentina S.A. ADR (TEO) Stock Records 32.38% Quarterly Movement - The News Heater
Guru Fundamental Report for ARGXBenjamin Graham - Nasdaq
Orphan Designated Drugs Market Analysis: Key Trends, Players and Forecasts for Future Growth - GlobeNewswire Inc.
Is Argenx (ARGX) Outperforming Other Medical Stocks This Year? - Yahoo Finance
argenx SE : The stock is approaching a major resistance level -January 29, 2025 at 04:11 am EST - Marketscreener.com
argenx's SWOT analysis: biotech stock soars on VYVGART success, pipeline promise - Investing.com India
Argenx stock price target raised to $717 by H.C. Wainwright - Investing.com India
Are Medical Stocks Lagging Argenx (ARGX) This Year? - Yahoo Finance
Truist Securities raises argenx stock rating to Buy, says will exceed Vision 2030 - Investing.com
Jefferies raises argenx stock target, reaffirms buy on global sales result - Investing.com
argenx's SWOT analysis: biotech stock soars on vyvgart success - Investing.com
Piper Sandler increases argenx stock price target on revised estimates - Investing.com
Argenx stock soars to all-time high of $645.31 amid robust growth - Investing.com
Argenx Secures Japanese Approval for VYVDURA in CIDP Treatment - Yahoo Finance
Weekly Upgrades and Downgrades - InvestorPlace
Argenx stock soars to all-time high of $630.4 amid robust growth By Investing.com - Investing.com South Africa
Argenx stock soars to all-time high of $630.4 amid robust growth - Investing.com
argenx's SWOT analysis: biotech stock soars on VYVGART success - Investing.com
Upcoming Nasdaq-100 changes could boost the stocks of these 11 companies - MSN
Argenx Expands Autoimmune Portfolio With Additional Vyvgart Approvals as Pipeline Develops - Morningstar
Piper Sandler maintains stock target on argenx, cites growth potential - Investing.com
Argenx stock soars to all-time high of $620.29 - Investing.com
10 High Growth Healthcare Stocks to Invest in Now - Insider Monkey
Argenx stock soars to all-time high of $612.64 amid robust growth By Investing.com - Investing.com South Africa
Argenx stock soars to all-time high of $612.64 amid robust growth - Investing.com India
argenx's SWOT analysis: biotech firm's stock soars on VYVGART success - Investing.com
Jefferies reaffirms Buy rating on argenx stock, ups target amid promising trial updates - Investing.com India
Can Argenx stock sustain its autoimmune category dominance? Oppenheimer weighs in - Investing.com
Barclays bullish on argenx stock after positive trial results - Investing.com
Barclays bullish on argenx stock after positive trial results By Investing.com - Investing.com South Africa
argenx shares see price target boosted by Raymond James, Strong Buy rating upheld - Investing.com
10 Biggest Biotechnology Companies - Investopedia
Argenx upgraded at Wolfe on myasthenia gravis dominance - MSN
argenx stock boosted by Wolfe, citing dominance in MG and profitability ahead - Investing.com
Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China - Yahoo Finance
Scotiabank raises argenx stock PT to $715, highlights efgartigimod's potential - Investing.com India
argenx SE's SWOT analysis: biotech stock poised for growth amid challenges - Investing.com
Deutsche Bank raises argenx target by EUR25, acknowledges momentum despite valuation - Investing.com
argenx ADR Clears Technical Benchmark, Hitting 90-Plus RS Rating - Investor's Business Daily
Argenx shares target raised by H.C. Wainwright, citing strong sales performance - Investing.com
Argenx Q3 Revenue, EPS Beats Excite Bullish Biotech Analysts: 'Most Enviable I&I Pipeline In Entire Industry' - Benzinga
0.16%
1.81%
大文字化:
|
ボリューム (24 時間):